Story has been updated to add attorney comment.

Last week, the U.S. Food and Drug Administration asked Endo Pharmaceuticals Inc. of Newark, New Jersey, to remove Opana ER, its extended-release version of oxymorphone hydrochloride, from the market after the agency found a likelihood of abuse by crushing up and injecting the pills. According to the FDA, it is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the risks of abuse.